Skip to main content

Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables

Rheumatology International volume 28, Article number: 1223 (2008) Cite this article

Abstract

We evaluated the prevalence and characteristics associated with hyperhomocysteinemia in ankylosing spondylitis (AS). Ninety-seven patients with AS were compared with 97 controls. The assessment included clinical characteristics, disease activity (BASDAI), functioning (BASFI), history of drugs, and erythrocyte sedimentation rate (ESR). Total serum homocysteine (tHcy) was determined by fluorescence polarization immunoassay. A higher frequency of hyperhomocysteinemia (>15 μmol/L) was observed in AS (12 vs. 1%, P = 0.002). In the multivariate analysis the risk for hyperhomocysteinemia was increased in patients with higher score of HAQ-S (OR = 5.27, 95% CI: 1.29–21.44) and higher ESR (OR = 1.09, 95% CI: 1.02–1.18). No statistical associations was observed between hyperhomocysteinemia with other variables including methotrexate or sulfasalazine utilization. In conclusion, this study found a significant prevalence of hyperhomocysteinemia in Mexican patients with AS mainly associated to a worst functional impairment. Further follow-up studies are required to evaluate the risk of cardiovascular disease in these patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274:1049–1057. doi:10.1001/jama.274.13.1049

    PubMed  Article  CAS  Google Scholar 

  2. Peters M, van der Horst-Bruinsma I, Dijkmans B, Nurmohamed M (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592. doi:10.1016/j.semarthrit.2004.07.010

    PubMed  Article  Google Scholar 

  3. Braun J, Pincus T (2002) Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20(Suppl 28):S16–S22

    PubMed  CAS  Google Scholar 

  4. Wei JC, Jan MS, Yu CT, Huang YC, Yang CC, Tsou HK et al (2007) Plasma homocysteine status in patients with ankylosing spondylitis. Clin Rheumatol 26:739–742. doi:10.1007/s10067-006-0396-x

    PubMed  Article  Google Scholar 

  5. Malesci D, Niglio A, Mennillo GA, La Montagna G (2007) High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 26:710–714. doi:10.1007/s10067-006-0380-5

    PubMed  Article  Google Scholar 

  6. Xu XY, Zhou WH, Xiao CS, Li XF, Wang LY (2005) A clinical study of hyperhomocysteinemia in rheumatological diseases. Zhonghua Nei Ke Za Zhi 44:111–114

    PubMed  CAS  Google Scholar 

  7. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368. doi:10.1002/art.1780270401

    PubMed  Article  Google Scholar 

  8. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291

    PubMed  CAS  Google Scholar 

  9. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285

    PubMed  CAS  Google Scholar 

  10. Daltroy LH, Larson MG, Roberts NW, Liang MH (1990) A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 17:946–950

    PubMed  CAS  Google Scholar 

  11. Shipchandler MT, Moore EG (1995) Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. Clin Chem 41:991–994

    PubMed  CAS  Google Scholar 

  12. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala M (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167–2172

    PubMed  Google Scholar 

  13. Lopez-Olivo MA, Gonzalez-Lopez L, Garcia-Gonzalez A, Villa-Manzano AI, Cota-Sanchez AR, Salazar-Paramo M et al (2006) Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis. Scand J Rheumatol 35:112–116. doi:10.1080/03009740510026922

    PubMed  Article  CAS  Google Scholar 

  14. Joubert LM, Manore MM (2006) Exercise, nutrition, and homocysteine. Int J Sport Nutr Exerc Metab 16:341–361

    PubMed  CAS  Google Scholar 

  15. Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S (2002) Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29:875–882

    PubMed  CAS  Google Scholar 

  16. Schroecksnadel K, Frick B, Fiegl M, Winkler C, Denz HA, Fuchs D (2007) Hyperhomocysteinaemia and immune activation in patients with cancer. Clin Chem Lab Med 45:47–53. doi:10.1515/CCLM.2007.012

    PubMed  Article  CAS  Google Scholar 

  17. Jensen OK, Rassmussen C, Mollerup F, Christensen PB, Hansen H, Ekelub S et al (2002) Hyperhomocysteinemia in rheumatoid arthritis: influence of methotrexate treatment and folic acid supplementation. J Rheumatol 29:1615–1618

    PubMed  CAS  Google Scholar 

  18. Hornung N, Ellingsen T, Stengaard-Pedersen K, Poulsen JH (2004) Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. J Rheumatol 31:2374–2381

    PubMed  CAS  Google Scholar 

  19. Haagsma CJ, Blom HJ, van Riel PL, van’t Hof MA, Giesendorf BA, Van Oppenraaij-Emmerzaal D et al (1999) Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 58:79–84

    PubMed  CAS  Article  Google Scholar 

  20. Hoekstra M, Haagsma CJ, Doelman CJ, van de Laar MA (2005) Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis 64:141–143. doi:10.1136/ard.2003.019828

    PubMed  Article  CAS  Google Scholar 

  21. Medina M, Urdiales JL, Amores-Sanchez MI (2001) Roles of homocysteine in cell metabolism: old and new functions. Eur J Biochem 268:3871–3882. doi:10.1046/j.1432-1327.2001.02278.x

    PubMed  Article  CAS  Google Scholar 

  22. Lusis AJ (2000) Atherosclerosis. Nature 407:233–241. doi:10.1038/35025203

    PubMed  Article  CAS  Google Scholar 

  23. Voutilainen S, Morrow JD, Roberts LJ 2nd, Alfthan G, Alho H, Nyyssonen K, Salonen JT (1999) Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol 19:1263–1266

    PubMed  CAS  Google Scholar 

  24. Dudman NP, Temple SE, Guo XW, Fu W, Perry MA (1999) Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats In vivo. Circ Res 84:409–416

    PubMed  CAS  Google Scholar 

  25. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L, Thomson A, Ueland PM, Ebrahim SB (1999) Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 82:448–454

    PubMed  CAS  Google Scholar 

  26. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S (1999) Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131:363–375

    PubMed  CAS  Google Scholar 

  27. Wald DS, Law M, Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325:1202. doi:10.1136/bmj.325.7374.1202

    PubMed  Article  Google Scholar 

  28. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D’Agostino RB, Wolf PA, Jacques PF, Wilson PW (1999) Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 159:1077–1080. doi:10.1001/archinte.159.10.1077

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported by the Mexican Institute for Social Security (Instituto Mexicano del Seguro Social).

Conflict of interest statement

None.

Author information

Affiliations

  1. Department of Internal Medicine-Rheumatology, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS) and Postgraduate Program of Public Health Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico

    Laura Gonzalez-Lopez

  2. Department of Internal Medicine-Rheumatology, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS) and Postgraduate Program of Pharmacology, Centro Universitario De Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico

    Julia D. Sanchez-Hernandez, Erika A. G. Aguilar-Chavez & Alberto I. Villa-Manzano

  3. Department of Blood Chemistry, Central Laboratory, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Mexico

    Adolfo R. Cota-Sanchez

  4. Anderson Hospital, Houston, TX, USA

    Maria A. Lopez-Olivo

  5. Department of Blood Chemistry, Hospital General Regional 110, IMSS, Guadalajara, Mexico

    Ricardo Ortega-Flores

  6. Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico

    Genadia L. Espinoza-Magaña

  7. Hospital General de Zona 6, Instituto Mexicano del Seguro Social (IMSS) and Postgraduate Program of Medical Sciences, Universidad de Colima, Colima, Mexico

    Wendoline Rojo-Contreras

  8. Department of Internal Medicine-Cardiology, Hospital General Regional 45, IMSS, Guadalajara, Mexico

    Ernesto G. Cardona-Muñoz

  9. Section for Clinical Studies in Musculoskeletal and Autoimmune Diseases, Clinical Epidemiology Research Unit, Hospital de Especialidades, IMSS, Postgraduate Public Health Sciences Program and Postgraduate Program of Pharmacology, Universidad de Guadalajara, Guadalajara, Mexico

    Jorge I. Gamez-Nava

  10. Av. Salto del Agua 2192 Col. Jardines del Country, CP 44210, Guadalajara, Jalisco, Mexico

    Jorge I. Gamez-Nava

Authors
  1. Laura Gonzalez-Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia D. Sanchez-Hernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erika A. G. Aguilar-Chavez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adolfo R. Cota-Sanchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria A. Lopez-Olivo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alberto I. Villa-Manzano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ricardo Ortega-Flores
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Genadia L. Espinoza-Magaña
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wendoline Rojo-Contreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ernesto G. Cardona-Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jorge I. Gamez-Nava
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jorge I. Gamez-Nava.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gonzalez-Lopez, L., Sanchez-Hernandez, J.D., Aguilar-Chavez, E.A.G. et al. Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables. Rheumatol Int 28, 1223 (2008). https://doi.org/10.1007/s00296-008-0687-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00296-008-0687-4

Keywords

  • Hyperhomocysteinemia
  • Prevalence
  • Ankylosing spondylitis
  • BASFI